It can be challenging to cross-link the eyes of wheelchair users – for the patient and clinic staff alike. One example of just how challenging
Accelerated CXL. For many years now, cornea specialists have used the excellent 10 minutes at 9 mW/cm² protocol to cross-link adults with keratoconus. Why? Because
Prof. Farhad Hafezi, Medical Director of the ELZA Institute, Zurich, Switzerland was the second-placed winner of the VSY Biotechnology’s Ophthalmology Star awards 2021, presented at
Corneal cross-linking (CXL) has been used in the clinic for over 20 years now, but if you ever wanted to know what the future of
Prof. Farhad Hafezi was recently profiled in the Swiss newspaper, Limmattaler Zeitung, in which he discussed everything from his pioneering research into corneal cross-linking (CXL), how he has spent the last two decades improving CXL to better treat not just keratoconus, but infections of the cornea too – in a way that doesn’t require antibiotics or antifungal drugs to kill the infectious organisms.
ELZA at ESCRS 2021. This year’s annual congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2021) will be held at the RAI
Researchers from ELZA, the ETH Zurich, the University of Zurich and the University of South Florida investigate corneal biomechanics in a mouse model for Ehlers-Danlos
Being a member of a scientific journal’s Editorial Board is an important responsibility. The journal places a lot of trust in board members. They determine
Here’s the latest news from Expertscape: ELZA’s consultant surgeons are world leaders! Prof. Farhad Hafezi, MD, PhD, FARVO ranked in the world’s top ten –
